It looks like Biogen Inc.’s Nrf2 activator, Skyclarys (omaveloxolone), will maintain its status as the sole therapy approved for treating patients with Friedreich’s ataxia (FA), at least for now. The ...

Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock following its Q3 earnings release.

In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Larimar Therapeutics reports ...

Shares of Larimar Therapeutics rose in premarket trading after the company said it would share data from its study for its proposed treatment of Friedreich's ataxia, a neurodegenerative disorder, ...